Form 4: Caribou Biosciences' Chief Medical Officer, Tina M. Albertson, Acquires 300,000 Stock Options

Tina M. Albertson, Chief Medical Officer of Caribou Biosciences, acquired options to purchase 300,000 shares of common stock on August 19, 2024.

Summary

• On August 19, 2024, Tina M. Albertson, the Chief Medical Officer of Caribou Biosciences, Inc. (CRBU), acquired options to purchase 300,000 shares of the company's common stock.
• The exercise price of these options is $2.18 per share.
• The options vest over a 4-year period, with 25% vesting on August 19, 2025, and the remainder vesting monthly over the subsequent 36 months, contingent upon continued service to Caribou Biosciences.
• The options expire on August 18, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The grant to the CMO could be seen as a sign of confidence, but it's not a strong signal.

Positives

• The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry. Stock options are frequently used to incentivize key personnel.

Comparison to Industry Standards

• Granting stock options to key executives is a common practice in the biotech industry to align their interests with those of shareholders.
• The vesting schedule of 25% after one year followed by monthly vesting is a fairly standard arrangement.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The granting of stock options to the Chief Medical Officer aligns her interests with those of the shareholders, potentially incentivizing her to drive company success and increase shareholder value.

Key Dates